Post by PPD

Cardiovascular outcomes trials (CVOTs) are among the most complex and resource-intensive studies in drug development — and small execution decisions can have a big impact. New research from the Tufts Center for the Study of Drug Development explores how integrating clinical research and manufacturing capabilities may help sponsors improve operational efficiency, accelerate timelines, and increase program value in late-stage cardiovascular and diabetes trials. As cardiometabolic pipelines continue to expand, sponsors that align clinical and manufacturing execution may be better positioned to maximize asset value, improve ROI and accelerate patient access to innovative therapies. Download the white paper to explore the data, methodology and implications for CVOTs: http://spr.ly/6041BDm5N9